Multidisciplinary team meetings — challenges of implementation science
Multidisciplinary team meetings — challenges of implementation science, Published online: 14 December 2018; doi:10.1038/s41571-018-0148-2Multidisciplinary team meetings have several flaws; herein, we propose approaches for cancer centres to transform these limitations into improvements in the quality control of oncological care and into research opportunities. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 14, 2018 Category: Cancer & Oncology Authors: N. Gopalakrishna Iyer Melvin L. K. Chua Source Type: research
Somatic and germline genomics in paediatric acute lymphoblastic leukaemia
Somatic and germline genomics in paediatric acute lymphoblastic leukaemia, Published online: 13 December 2018; doi:10.1038/s41571-018-0136-6Herein, advances in our understanding of the genomic landscape of childhood acute lymphoblastic leukaemia (ALL), encompassing both somatic and germline alterations, are reviewed. The clinical implications of these alterations, particularly those in the germ line, are discussed with regard to susceptibility to ALL, treatment responses and therapy-related toxicities. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 13, 2018 Category: Cancer & Oncology Authors: Ching-Hon Pui Kim E. Nichols Jun J. Yang Source Type: research
Radical shifts in the first-line management of metastatic renal cell carcinoma
Radical shifts in the first-line management of metastatic renal cell carcinoma, Published online: 11 December 2018; doi:10.1038/s41571-018-0146-4In 2018, the results of multiple phase III trials in metastatic renal cell carcinoma (mRCC) were presented. A phase III noninferiority trial demonstrated the importance of careful patient selection before cytoreductive nephrectomy. Additionally, three randomized phase III trials demonstrated the superiority of combination therapy with an immune-checkpoint inhibitor backbone versus sunitinib in patients with treatment-naive mRCC. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 11, 2018 Category: Cancer & Oncology Authors: Moshe C. Ornstein Brian I. Rini Source Type: research
A banner year for immunotherapy and targeted therapy
A banner year for immunotherapy and targeted therapy, Published online: 11 December 2018; doi:10.1038/s41571-018-0138-4In 2018, advances in the treatment of non-small-cell lung cancer (NSCLC) have been observed both in trials of immunotherapies and targeted agents, leading to dramatically improved options for patients with metastatic and stage III NSCLC. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 11, 2018 Category: Cancer & Oncology Authors: Jennifer W. Carlisle Suresh S. Ramalingam Source Type: research
Cancer immunoediting and resistance to T cell-based immunotherapy
Cancer immunoediting and resistance to T cell-based immunotherapy, Published online: 06 December 2018; doi:10.1038/s41571-018-0142-8The mechanisms of resistance to immunotherapy seem to broadly overlap with the immunoediting process whereby cancers evade detection by the immune system. The authors of this Review discuss these interactions as well as the strategies that can be used to overcome therapeutic resistance (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 6, 2018 Category: Cancer & Oncology Authors: Jake S. O ’Donnell Michele W. L. Teng Mark J. Smyth Source Type: research
A framework for the development of effective anti-metastatic agents
A framework for the development of effective anti-metastatic agents, Published online: 04 December 2018; doi:10.1038/s41571-018-0134-8Most cancer-related deaths are attributable to metastasis, but few treatments are specifically designed to disrupt this process. In this Position Paper, representatives of the joint Cancer Research UK and Cancer Therapeutics CRC Australia Metastasis Working Group describe the challenges associated with discovering and developing anticancer agents designed specifically to prevent or delay the metastatic outgrowth of cancer and provide guidance on how these challenges might be overcome. (Sourc...
Source: Nature Clinical Practice Oncology - December 4, 2018 Category: Cancer & Oncology Authors: Robin L. Anderson Theo Balasas Juliana Callaghan R. Charles Coombes Jeff Evans Jacqueline A. Hall Sally Kinrade David Jones Paul S. Jones Rob Jones John F. Marshall Maria Beatrice Panico Jacqui A. Shaw Patricia S. Steeg Mark Sullivan Warwick Tong Andrew D Source Type: research
Balancing opioid analgesia with the risk of nonmedical opioid use in patients with cancer
Balancing opioid analgesia with the risk of nonmedical opioid use in patients with cancer, Published online: 04 December 2018; doi:10.1038/s41571-018-0143-7Patients with cancer might be at a higher risk of nonmedical opioid use than was previously thought; however, opioid analgesics remain the gold standard to treat cancer-related pain. The authors of this Review examine the role of opioids in cancer-related pain, the risk of substance use disorder and methods to achieve the right balance between both to ensure safe opioid use. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 4, 2018 Category: Cancer & Oncology Authors: Joseph Arthur Eduardo Bruera Source Type: research
Adjuvant TKIs — a long-term matter
Adjuvant TKIs — a long-term matter, Published online: 28 November 2018; doi:10.1038/s41571-018-0144-6Adjuvant TKIs — a long-term matter (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 28, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Clinical potential of mass spectrometry-based proteogenomics
Clinical potential of mass spectrometry-based proteogenomics, Published online: 28 November 2018; doi:10.1038/s41571-018-0135-7Precision medicine approaches to the treatment of cancer are largely reliant on genomic analysis alone. In this Perspective the authors provide a rationale for the incorporation of analysis of the proteome, which is a rich source of biological heterogeneity, into the treatment and management of patients with cancer. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 28, 2018 Category: Cancer & Oncology Authors: Bing Zhang Jeffrey R. Whiteaker Andrew N. Hoofnagle Geoffrey S. Baird Karin D. Rodland Amanda G. Paulovich Source Type: research
Integrating molecular nuclear imaging in clinical research to improve anticancer therapy
Integrating molecular nuclear imaging in clinical research to improve anticancer therapy, Published online: 27 November 2018; doi:10.1038/s41571-018-0123-yIntegrating molecular nuclear imaging in clinical research has great potential to improve anticancer therapy, particularly through the development of imaging biomarkers. Herein, the multistage process of developing novel molecular imaging biomarkers is discussed, highlighting both the challenges that have restricted the use of molecular imaging in clinical oncology research and future opportunities in this area. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 27, 2018 Category: Cancer & Oncology Authors: Elisabeth G. E. de Vries Laura Kist de Ruijter Marjolijn N. Lub-de Hooge Rudi A. Dierckx Sjoerd G. Elias Sjoukje F. Oosting Source Type: research
Neoadjuvant pembrolizumab shows promise
Neoadjuvant pembrolizumab shows promise, Published online: 26 November 2018; doi:10.1038/s41571-018-0131-yNeoadjuvant pembrolizumab shows promise (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 26, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Second elotuzumab triplet efficacious in MM
Second elotuzumab triplet efficacious in MM, Published online: 26 November 2018; doi:10.1038/s41571-018-0137-5Second elotuzumab triplet efficacious in MM (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 26, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research
Donors with CHIP are safe for allogeneic HSCT
Donors with CHIP are safe for allogeneic HSCT, Published online: 26 November 2018; doi:10.1038/s41571-018-0140-xDonors with CHIP are safe for allogeneic HSCT (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 26, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Lorlatinib effective in multiple settings
Lorlatinib effective in multiple settings, Published online: 26 November 2018; doi:10.1038/s41571-018-0141-9Lorlatinib effective in multiple settings (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 26, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Faecal transplantation reverses colitis
Faecal transplantation reverses colitis, Published online: 26 November 2018; doi:10.1038/s41571-018-0139-3Faecal transplantation reverses colitis (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 26, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
